Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years~* Onset of severe sepsis within the previous 24 hours~* Must be receiving antibiotic therapy~* Informed consent form signed by patient, legal next-of-kin or legal guardian~* Able to take medication by mouth or feeding tube~Exclusion Criteria:~* Receipt of investigational medication within 4 weeks prior to participation in the study~* Pregnant or breast-feeding~* Severe congestive heart failure~* Known severe HIV infection~* Presence of severe burns~* Patients on high dose immunosuppressants~* Patients whose death is considered imminent~* Patients whose life expectancy for concurrent illness is less than 6 months~* Severe hypoxic encephalopathy or persistent vegetative state~* Severe liver disease~* Patient, legal representative or patient's primary physician not committed to providing full, aggressive life support

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Talactoferrin alfa
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).